Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

BioMarin pays $70 million upfront for a long-acting Fabry therapy, while Ferring agrees to acquire fertility biotech Gameto in a deal worth up to $1.38B. Credit: Stock.Adobe.com/Parradee

October 29th, 2026

Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion

BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.

Dave Sunderhaft, Chief Operating Officer nPhase, Inc.

October 29th, 2026

Rebuilding Clinical Data Workflows for the AI Era

As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.

October 29th, 2026

How Preventative Medications May Impact the Lingering Impact of COVID-19

Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.

October 29th, 2026

How Digital Twins Impact Recruiting During Research

Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.

Astellas secures an option on Audax’s preclinical IL-12 fusion DAX-044 in a deal worth up to $1.34 billion; EVERSANA acquires HEOR firm Estima Scientific. Credit: Stock.Adobe.com/Yingyaipumi

October 28th, 2026

Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific

Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.

October 28th, 2026

Should There be More of a Focus on Developing Preventative Medications

Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.

Sam Anwar, Chief Technology Officer at eClinical Solutions

October 28th, 2026

The Next Biopharma Revolution: Quantum Computing

The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities

October 28th, 2026

What Outcomes Digital Twins Can be Used to Predict

Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.

Trending on PharmExec

Rebuilding Clinical Data Workflows for the AI Era

The Next Biopharma Revolution: Quantum Computing

Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific

Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial

Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion